Is Gitlab a Buy Under $80?
The growing market for DevOps platforms benefits GitLab (GTLB) and the company expects significant revenue growth in the current quarter. However, the company’s weak bottom line is a concern. The…
The growing market for DevOps platforms benefits GitLab (GTLB) and the company expects significant revenue growth in the current quarter. However, the company’s weak bottom line is a concern. The…
By Dhirendra Tripathi Investing.com – Dollar Tree stock (NASDAQ:DLTR) traded 1.2% lower Monday after the company’s battle with activist investor Mantle Ridge became public Sunday, suggesting the distraction may last…
By Geoffrey Smith Investing.com — U.S. stocks opened lower on Monday as risk appetite dried up ahead of the Federal Reserve’s policy-setting meeting that takes place on Tuesday and Wednesday.…
WASHINGTON (Reuters) – The U.S. Supreme Court on Monday declined to hear a bid by Johnson & Johnson (NYSE:JNJ) to throw out a lawsuit brought by the state of Mississippi…
By Sam Boughedda Investing.com — Foghorn Therapeutics Inc (NASDAQ:FHTX) jumped 55% to $18.60 in early Monday trading on news of a strategic collaboration with Eli Lilly and Company (NYSE:LLY) to…
By Lawrence Hurley and Ludwig Burger WASHINGTON (Reuters) -The U.S. Supreme Court on Monday asked President Joe Biden’s administration for its views on whether the justices should hear Bayer AG…
The shares of semiconductor-based power electronics solutions provider Monolithic (MPWR) have declined 6.4% in price over the past month. The stock is now trading below its 50-day moving average. However,…
As the hybrid work-structure culture regains traction owing to the resurgence of COVID-19 cases, the demand for information technology services is set to accelerate. So, we think it could be…
UpStart Holdings (UPST) operates a cloud-based, artificial intelligence (AI) lending platform that uses alternative data to measure credit risk and originate loans. UPST is down more than 50% over the…
By Dhirendra Tripathi Investing.com – Bellus Health stock (NASDAQ:BLU) surged 64% Monday after the company revealed positive results from a trial of a treatment it is developing against refractory chronic…